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ABSTRACT
The adaptor protein-2 sigma subunit (AP2s), encodedbyAP2S1, forms a heterotetrameric complex,with AP2a, AP2b, andAP2m subunits,
that is pivotal for clathrin-mediated endocytosis, and AP2s loss-of-function mutations impair internalization of the calcium-sensing
receptor (CaSR), a G-protein–coupled receptor, and cause familial hypocalciuric hypercalcemia type-3 (FHH3). Mice with AP2smutations
thatwould facilitate investigations of the in vivo role of AP2s, arenot available, andwe therefore embarkedonestablishing suchmice.We
screened >10,000 mice treated with the mutagen N-ethyl-N-nitrosourea (ENU) for Ap2s1 mutations and identiﬁed 5 Ap2s1 variants,
comprising 2 missense (Tyr20Asn and Ile123Asn) and 3 intronic base substitutions, one of which altered the invariant donor splice site
dinucleotidegt togc. Three-dimensionalmodelingandcellular expressionof themissenseAp2s1variantsdidnot reveal themtoalterAP2s
structure or CaSR-mediated signaling, but investigation of the donor splice site variant revealed it to result in an in-frame deletion of 17
evolutionarily conservedaminoacids (del17) that formedpart of theAP2sa1-helix,a1-b3 loop, andb3strand.Heterozygousmutantmice
(Ap2s1+/del17) were therefore established, and these had AP2s haplosufﬁciency but were viable with normal appearance and growth.
Ap2s1+/del17 mice, when compared with Ap2s1+/+ mice, also had normal plasma concentrations of calcium, phosphate, magnesium,
creatinine, urea, sodium, potassium, and alkaline phosphatase activity; normal urinary fractional excretion of calcium, phosphate, sodium,
and potassium; and normal plasma parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D (1,25(OH)2) concentrations. However,
homozygous Ap2s1del17/del17micewere non-viable and died between embryonic days 3.5 and 9.5 (E3.5–9.5), thereby indicating that AP2s
likelyhas important rolesat theembryonicpatterningstagesandorganogenesisof theheart, thyroid, liver, gut, lungs,pancreas, andneural
systems. Thus, our studies have established a mutant mouse model that is haplosufﬁcient for AP2s. © 2017 The Authors. JBMR Plus is
published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.
KEY WORDS: DISORDERS OF CALCIUM/PHOSPHATE METABOLISM; PTH/VIT D/FGF23; PARATHYROID-RELATED DISORDERS; CELL/TISSUE
SIGNALING – ENDOCRINE PATHWAYS; ANIMAL MODELS – GENETIC ANIMAL MODELS
Introduction
Familial hypocalciuric hypercalcemia (FHH) is an autosomaldominant disorder characterized by lifelong elevations in
serum calcium concentrations in association with normal or
mildly elevated serum parathyroid hormone (PTH) concentra-
tions and low urinary calcium excretion (urinary calcium
clearance to creatinine clearance ratio <0.01).(1,2) FHH is a
genetically heterogeneous disorder with three recognized forms
referred to as FHH types 1–3 (FHH1–3).(3) FHH1 (OMIM #145980)
is caused by heterozygous loss-of-function mutations of the
calcium-sensing receptor (CaSR), which is a G-protein–coupled
receptor (GPCR), that preferentially activates the G-protein
subunit aq/11 (Gaq/11) family, with resulting increases in
phospholipase C (PLC) activity and elevations of inositol
1,4,5-trisphosphate (IP3) that lead to rapid increases in
intracellular calcium (Ca2þi) concentrations.
(4,5) Initiation of
these CaSR-signaling pathways leads to reduced circulating
PTH and increased urinary calcium concentrations.(5) Loss-of-
function mutations of the Ga11 subunit, encoded by the GNA11
gene, cause FHH2 (OMIM #145981),(6,7) whereas FHH3 (OMIM
#600740) is causedbyheterozygous loss-of-functionmutationsof
the adaptor protein-2 s subunit (AP2s), encoded by the AP2S1
gene.(8) AP2s is the smallest subunit of the heterotetrameric AP2
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protein, which comprises two large subunits, a and b, and two
smaller subunits m and s.(9) AP2 has a fundamental role in
clathrin-mediated endocytosis of GPCRs such as the CaSR,(10) and
to facilitate this, the AP2a andb subunits have large appendages
that bind to the clathrin coat protein, accessory proteins (eg,
b-arrestin), and plasma membrane phospholipids, thereby
facilitating their roles as endocytic hubs.(11) The AP2m and s
subunits are involved in binding to motifs of cargo proteins with
the m subunit recognizing tyrosine-based motifs and the s
subunit dileucine-based motifs.(9) All of the FHH3-associated
mutations reported to date involve the AP2s Arg15 residue, and
each of the 3 different missense mutations (Arg15Cys, Arg15His,
and Arg15Leu)(8) are postulated to disrupt the polar contacts
between the AP2s Arg15 residue and the dileucine motif in the
cytoplasmic tail of the CaSR to target it for endocytosis.(8,9,12)
Mouse models harboring deleted alleles for CaSR, Ga11, and
Gaq have been established, and their investigations have
provided important insights into the pathophysiological
mechanisms of these disorders of calcium metabolism. Thus,
mice deleted for one CaSR allele (ie, heterozygous knockout
CaSR+/ mice) have been shown to develop modest hypercal-
cemia with relative hypocalciuria, and inappropriately elevated
serum PTH, consistent with features of FHH1 in patients.(13)
In addition, homozygous knockout mice, ie, CaSR-/-, have been
demonstrated to develop early onset of severe hypercalcemia in
association with increased serum PTH concentrations, parathy-
roid hyperplasia, and bone demineralization that resulted in
death by age 30 days.(13,14) These ﬁndings in CaSR-/- mice are
representative of the features found in patients with neonatal
severe primary hyperparathyroidism (NSHPT), who usually
harbor homozygous or compound heterozygous CaSR muta-
tions.(3,15–17) Moreover, studies of CaSR-/-/Pth-/- mice, which did
not have increased neonatal lethality or skeletal abnormalities,
have shown that CaSR has PTH-independent roles in calcium
homeostasis.(18) These PTH-independent roles of the CaSR,
which are of importance in defending against hypercalcemia
and in maintaining normocalcemia, include CaSR-stimulated
calcitonin secretion and increased renal calcium excretion.(19)
Mice with germline deletions of Ga11 and Gaq alleles have also
been generated, and Gna11-/- and Gnaq-/- have been reported to
not develop abnormalities of calcium homeostasis.(20) However,
parathyroid-speciﬁc deletions of both copies of Ga11 and Gaq
did result in hypercalcemia but without hypocalciuria, thereby
indicating critical roles for Ga11 and Gaq in mediating inhibition
of PTH secretion by extracellular calcium [Ca2þe].
(20) To date,
mice deleted for Ap2s1 or harboring AP2s loss-of-function
mutations have not been reported, and we therefore pursued
studies to establish such mice by screening a DNA archive of
>10,000 samples from male mice that had mutations induced
by treating them with N-ethyl-N-nitrosourea (ENU).
ENU is an alkylating agent that primarily introduces point
mutations via transfer of the ENU alkyl group to the DNA base
followed by mispairing and subsequent base pair substitution
during the next round of DNA replication.(21,22) ENU mutagenesis
programs utilize two complementary approaches that are
phenotype-driven and genotype-driven screens. In phenotype-
driven screens, offspring of mutagenized mice are assessed for
abnormalities in a hypothesis-generating strategy, which may
elucidate new genes, pathways, and mechanisms for disease
phenotypes.(21,22) Genotype-driven screens in which mutations in
the gene of interest are sought are hypothesis-driven and are
feasible by available parallel archives of tissue-DNA and sperm
samples from mutagenized male mice.(21,22) The archived tissue-
DNA samples from themutagenized male mice are used to search
for themutations in the gene of interest, and once thesemutations
are found, then a sperm sample from the male mouse with the
mutation is used for in vitro fertilization (IVF) of normal femalemice
to establish progeny with the mutation.(21,22) The probability of
ﬁnding three or more variant alleles in an archive of tissue-DNA
samples from >5000 ENU-mutagenized mice is >90%.(21) We
sought for such ENU-inducedAp2s1 variants in tissue-DNA samples
from >10,000 mice treated with ENU and identiﬁed ﬁve variants
thatwere further appropriately assessed for their in vitroand invivo
effects on CaSR signaling and calcium homeostasis, respectively.
Materials and Methods
Animals
Animal studies were carried out using guidelines issued by the
UK Medical Research Council in Responsibility in Use of Animals
for Medical Research (July 1993) and UK Home Ofﬁce project
license numbers (PPL30/2433 and PPL30/3271). ENU-treated G0
C57BL/6J male mice were mated to C3H/HeH (C3H) to produce
G1 progeny, and tissue-DNA samples from >10,000 G1 ENU
mutagenized male mice, together with their sperm, were
archived, as previously reported.(22) The tissue-DNA samples
were used to identify Ap2s1 variants by melt curve analysis of
PCR products utilizing a Lightscanner and gene-speciﬁc primers
(BioFire Diagnostics, Inc., Salt Lake City, UT, USA), and sperm
from mice with Ap2s1 variants was used for IVF to generate G2
progeny on a C3H background strain, as reported.(23) Heterozy-
gous mutant male and female mice were intercrossed to
generate homozygous mice, which were studied with their
heterozygous and wild-type littermates. Mice were fed on a
standard diet (Rat and Mouse number 3, Special Diet Services,
Essex, UK) that contained 1.15% calcium, 0.58% phosphate, and
4089 IU/kg of vitamin D, and provided with water ad libitum.(24)
DNA sequence analysis
Genomic DNA was isolated from auricular biopsies using DNA
extraction buffer (10mM NaCl, 20mM Tris-HCl, pH8.0, 1mM EDTA,
10% sodium dodecyl sulfate [SDS]) and Proteinase K solution
(ThermoFisher, Carlsbad, CA, USA).(23,24) Genomic DNA was used
with Ap2s1 gene-speciﬁc primers (Sigma-Aldrich, Gillingham, UK)
(Supplemental Table S1) to perform PCR ampliﬁcation, followed by
dideoxynucleotide sequencing using the BigDye Terminator v3.1
Cycle Sequencing Kit and an automated detection system (ABI 3730
Automated capillary sequencer, ThermoFisher), as previously
reported.(23–25) Polyphen-2 (http://genetics.bwh.harvard.edu/
pph2/)(26) and MutationTasting (http://www.mutationtaster.
org/)(27) were used to predict the effects of missense mutations.
Protein sequence alignment and three-dimensional
modeling
Protein sequences of AP2s were aligned using ClustalOmega
(http://www.ebi.ac.uk/Tools/msa/clustalo/).(28) PyMOL Molecu-
lar Graphics System (Version 1.8, Schr€odinger, LLC, Portland OR,
USA) was used to model the effects of the AP2s variants, using
the reported three-dimensional structure of AP2s.(8,9)
RNA extraction, reverse transcription-PCR (RT-PCR), and
quantitative PCR (qRT-PCR)
Total RNA was isolated from auricular biopsies using Trizol
reagent (ThermoFisher), as described.(29) cDNA was prepared
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from 1mg of RNA using the QuantiTect Reverse Transcription Kit
(Qiagen, Manchester, UK). RT-PCR was performed using gene-
speciﬁc primers encompassing Ap2s1 exons 1–3 (Supplemental
Table S1). PCR products were gel puriﬁed using the Geneclean
Kit (MP Biomedicals, Santa Ana, CA, USA) and cloned into the
pCR-BluntII-TOPO vector (Life Technologies, Carlsbad, CA, USA),
and the DNA sequences of the inserts determined using vector-
speciﬁc primers (Supplemental Table S1), as described.(25)
qRT-PCR reactions were performed using the QuantiTect SYBR
Green Kit (Qiagen) in four independent samples utilizing a
Rotorgene 5 (Qiagen), as described previously.(30) All qRT-PCR
test samples were normalized to the geometric mean of
three housekeeper genes (cyclin D1 [Ccnd1], glyceraldehyde
3-phosphate dehydrogenase [Gapdh], and phosphoglycerate
kinase 1 [Pgk1]), as described previously).(30) Threshold cycle
(CT) values were obtained from the start of the log phase on
Rotorgene Q Series Software and CT values analyzed in
Microsoft Excel 97–2010 using the Pfafﬂ method.(30) Data for
mutant mice were expressed relative to wild-type mice,
expressed as 1. For conﬁrmation of the effects of splicing,
cDNA was PCR ampliﬁed using gene-speciﬁc primers (Supple-
mental Table S1), utilizing methods previously described
(Sigma-Aldrich).(30) Predicted effect of mutations in introns
was assessed using the Alternative Splicing Site Predictor
(wangcomputing.com/asp/).(31)
Western blot analysis
Whole kidney lysates fromwild-type andmutant littermateswere
prepared using modiﬁed RIPA lysis buffer (50mM Tris HCl, pH7.4,
150mM NaCl, 1% (vol/vol) Igepal CA630, 0.5% sodium deoxy-
cholate, 0.1% SDS, 1mM sodium orthovanadate, Roche [Man-
nheim, Germany] protease inhibitors), as previously described.(25)
Lysates of ﬂow cytometry cells were prepared using NP40 lysis
buffer (50mMTris HCl, pH7.4, 1mMEDTA, 150mMNaCl, protease
inhibitors), as described.(25) The lysates were resuspended in
Laemmlibuffer; boiledandseparatedon10%SDSpolyacrylamide
electrophoresis gels; transferred to polyvinylidene diﬂuoride
membranes (Amersham Life Sciences, Buckinghamshire, UK),
whichwereblocked in 5%BSA/TBS-T; appropriately probedusing
antibodies for anAP2s, AP2m, AP2b, AP2a, calnexin, and/or CaSR;
andvisualizedusing Immuno-StarWesternCKit (BioRad,Hercules,
CA, USA) on a BioRad Chemidoc XRSþ system and densitometry
analysis was performed using ImageJ, as previously described.(25)
Statistical analyses were performed by 2-way ANOVA.
Cell culture and transfection for flow cytometry analysis
Wild-type and mutant pBI-CMV4-AP2S1 expression constructs
were generated, as described(12) and transiently transfected into
human embryonic kidney (HEK)-293 cells stably expressing CaSR
(HEK-CaSR)(7,8) using Lipofectamine 2000 (Life Technologies).
The bidirectional pBI-CMV4 cloning vector was used because it
facilitated the co-expression of AP2s and red ﬂuorescent protein
(RFP).(12) Site-directed mutagenesis was used to generate the
mutant AP2S1 constructs using the Quikchange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA,
USA) and gene-speciﬁc primers (Sigma-Aldrich), as described.(25)
Cells were maintained in Dulbecco’s Modiﬁed Eagle Medium
(DMEM)-Glutamax media (ThermoFisher) with 10% fetal bovine
serum (Gibco) and 400mg/mL geneticin (ThermoFisher) at
37 °C, 5% CO2. Transfection was conﬁrmed by Western blot
analyses and by visualizing RFP ﬂuorescence using an Eclipse
E400 ﬂuorescence microscope with a Y-FL Epiﬂuorescence
attachment and a triband 4,6-diamidino-2-phenylindole-FITC-
Rhodamine ﬁlter, and images taken using a DXM1200C digital
camera and NIS Elements software (Nikon), as described.(12)
Intracellular calcium measurements by flow cytometry
analysis
The Ca2þi responses of HEK293-CaSR cells expressing wild-type
variants or mutant AP2s proteins were assessed by a ﬂow
cytometry-based assay, as reported.(6,7,12) In brief, HEK293-CaSR
cells were cultured in T75 ﬂasks and transiently transfected 24
hours later with 8mg DNA.(6) Forty-eight hours after transfection,
cells were detached, resuspended in calcium (Ca2þ)- and
magnesium (Mg2þ)-free Hanks’ buffered saline solution
(HBSS), and loaded with 1mg/mL Indo-1-acetoxymethylester
(Indo-1-AM) for 1 hour at 37 °C. After removal of free dye, cells
were resuspended in Ca2þ- andMg2þ-free HBSS andmaintained
at 37°C. Transfected cells, in suspension, were stimulated by
sequentially adding Ca2þ to the Ca2þ- and Mg2þ-free HBSS to
increase the extracellular calcium concentration ([Ca2þe]) in a
stepwisemanner from 0 to 15mMand then analyzed on aMoFlo
modular ﬂow cytometer (Beckman Coulter, High Wycombe, UK)
by simultaneous measurements of RFP expression, Ca2þi-bound
Indo-1AM, and free Indo-1AM (ie, not bound to Ca2þi), using a
JDSU Xcyte UV laser (Coherent Radiation, Santa Clara, CA, USA),
on each cell at each [Ca2þe], as described.
(7) The peak mean
ﬂuorescence ratio of the Ca2þi transient response after each
individual stimulus was measured using Cytomation Summit
software (Beckman Coulter) and expressed as normalized
responses, as described.(7) Nonlinear regression of concentra-
tion-response curves was performed with GraphPad Prism
(GraphPad, La Jolla, CA, USA) using the normalized response at
each [Ca2þe] for each separate experiment for the determination
of EC50 (ie, [Ca
2þ
e] required for 50% of the maximal response).
The maximal signaling response was measured as a fold-change
of the peak transient Ca2þi response to the basal Ca
2þ
i response
measured at 0mM Ca2þe. The maximal signaling responses for
variant and mutant AP2s proteins were expressed as a
percentage of the wild-type AP2s protein maximal signaling
response. The mean EC50 obtained from 4 separate transfection
experiments were used for statistical comparison by using the
F test, and alterations in maximal signaling responses assessed
using the Mann-Whitney U test.
Metabolic cage studies, plasma and urine biochemistry,
and hormone analysis
Ten- to 12-week-old G2 mice were individually housed in
metabolic cages (Techniplast, Kettering, UK) for 24 hours with
free access to food and water.(32) Mice were allowed to
acclimatize to their environment over a 72-hour period, as
described,(32) before collection of 24-hour urine samples. Food
andwater intakewasmonitored, andmice were weighed before
and after the study. Twenty-four-hour urine samples were
collected in tubes containing sodium azide, and blood samples
were collected from the lateral tail vein or the internal jugular
vein into lithium heparin Microvette tubes (Sarstedt, Leicester,
UK) after terminal anesthesia, as previously described.(24) Urine
and plasma analyses were performed using a Beckman Coulter
AU680 analyzer, as reported.(24) Plasma and urine were
appropriately analyzed for sodium, potassium, total calcium,
phosphate, magnesium, urea, creatinine, and alkaline phospha-
tase activity on a Beckman Coulter AU680 analyzer. Plasma
calcium was adjusted for variations in albumin concentrations
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using the formula: (plasma calcium (mmol/L) [(plasma albu-
min (g/L) 30) 0.02], as reported.(24) Hormones were mea-
sured as follows: PTH using two-site ELISA speciﬁc for mouse
intact PTH (Immutopics, San Clemente, CA, USA), and 1,
25-dihydroxyvitamin D by a two-step process involving
puriﬁcation by immunoextraction and quantiﬁcation by enzyme
immunoassay (Immunodiagnostic Systems, Baldan, UK), as
described.(24,33) The fractional excretion of sodium, potassium,
and calcium were calculated using the formula Ux/PxPCr/UCr,
where Ux is the urinary concentration of the ﬁltered substance
(substance x) in mmol/L, Px is the plasma concentration of
substance x in mmol/L, UCr is the urinary concentration of
creatinine in mmol/L, and PCr is the plasma concentration
of creatinine in mmol/L.(24) A Mann-Whitney U test was used to
compare differences between wild-type andmutant littermates,
with a value of p< 0.05 being considered signiﬁcant for all
analysis.
Embryo analysis
Blastocysts at embryonic day 3.5 (E3.5) and embryos from E9.5
and E12.5 were collected by ﬂushing (E3.5) or dissecting the
uterine horns (E9.5 and E12.5) from pregnant females post-
mortem. Embryo age was conﬁrmed by assessing the develop-
ment of external structures as described.(34,35) Amniotic sacs
were collected for genotyping as described.(34)
Results
Identification of five Ap2s1 variants
Five Ap2s1 variants comprising 2 within exons, which predicted
missense substitutions Tyr20Asn and Ile123Asn, and 3 within
introns were identiﬁed by screening the tissue-DNA samples
from >10,000 ENU-mutagenized male mice for abnormalities
involving the ﬁve exons and intron-exon boundaries of the full-
length Ap2s1 gene (Fig. 1). The effects of these variants were
initially investigated by structural and in vitro functional studies
that examined for alterations in CaSR signaling via Gaq/11 and
increases in [Ca2þ]i.
Structural and in vitro signaling studies of the Tyr20Asn
and Ile123Asn AP2s variants
Of the twomissense variants, the Tyr20Asnwas located in exon 2
and was due to a T-to-A transversion, and the Ile123Asn was
located in exon 5 and was also due to a T-to-A transversion
(Fig. 1). Bioinformatic analysis using Polyphen-2 and Mutation-
Tasting software(26,27) predicted the AP2s variants (Tyr20Asn
and Ile123Asn) to be damaging and likely disease-causing
(Polyphen-2 score 1, MutationTasting score 0.99 for both
variants). In addition, the evolutionary conservation of the
Tyr20 and Ile123 residues in AP2s (Fig. 2A, B) and absence of
DNA sequence abnormalities that would alter the Tyr20 and
Ile123 residues from >66,000 exomes (combined from the
NHLBI-ESP and ExAC cohorts)(36) indicated that the Tyr20Asn,
which is located 5 residues C-terminal from the FHH3-associated
mutations at Arg15, and Ile123Asn variants could represent
pathogenic mutations rather than benign polymorphisms.
However, three-dimensional modeling of the variants using
the crystal structure of the AP2 heterotetramer in association
with a dileucine motif of a cargo protein(9) indicated that they
were unlikely to alter the structure of AP2 or disrupt polar
contacts with the dileucine motif (Fig. 2C, D). Thus, the Tyr20
residue, which lies within the second b-strand of AP2s that is
also the location of the FHH3-associated Arg15 mutations, is
situated away from the dileucine binding region and is also not
predicted to form contacts with any other residues in AP2s or in
the AP2 complex (Fig. 2C). The Ile123 residue, which is located
within a loop structure between 2 a-helices (a3–a4) that lie
close to the AP2a subunit (Fig. 2D), is also not predicted to
contact residues in AP2s or AP2a. Thus, the consequences of the
Tyr20Asn and Ile123Asn variants are difﬁcult to predict, and
functional in vitro studies were undertaken to determine the
effects on CaSR-mediated signaling.
CaSR-mediated signaling was assessed using HEK-CaSR cells
that were transiently transfected with pBI-CMV4 constructs that
expressed the wild-type or variant Asn20 and Asn123 AP2s
proteins, or FHH3-associated Arg15His (His15) AP2s mutant
protein,(7) and measuring their Ca2þi responses to alterations in
[Ca2þe]. Expression of the CaSR, AP2s, and RFPwas conﬁrmed by
ﬂuorescence microscopy and/or Western blot analysis (Fig. 3A,
B). AP2s expression was demonstrated to be similar in cells
transiently transfected with wild-type, variant AP2s, and
FHH3-mutant AP2s proteins (Fig. 3A, B). The Ca2þi responses
in wild-type, variant (Asn20 and Asn123), and FHH3-mutant
His15 AP2s-expressing cells were shown to increase in a
dose-dependent manner after stimulation with increasing
concentrations of Ca2þe (Fig. 3C, D). Exposure to a signiﬁcantly
greater [Ca2þe] was required to achieve half-maximal (EC50)
Ca2þi responses for cells expressing the FHH3-mutant His15
(Fig. 3C–F), as previously reported.(8) However, EC50 values for
Asn20 and Asn123 AP2s variants were not signiﬁcantly different
from WT responses (Fig. 3C–E). Thus, the FHH3-associated
His15 mutant-expressing cells showed rightward shifts in the
concentration-response curves, with signiﬁcantly elevated
mean EC50 values (p< 0.0001) of 4.61mM (95% conﬁdence
interval [CI] 4.43–4.81mM), compared with 3.40mM (95% CI
Fig. 1. Identiﬁcation of ﬁve variants of the Ap2s1 gene induced by ENU
in male mice. Schematic representation of the genomic organization of
the mouse Ap2s1 gene. The Ap2s1 gene consists of ﬁve exons with the
start (ATG) and stop (TGA) codons located in exons 1 and 5, respectively.
The 5 ENU-induced variants identiﬁed from screening tissue-DNA
samples from >10,000 male mice treated with ENU are highlighted by
dotted lines above the exons and introns. The variants are two missense
substitutions, Tyr20 and Ile123Asn, located in exons 2 and 5,
respectively, and three intronic variants located in introns 1, 2, and 4.
The locations of the FHH3-associated mutations (Arg15Cys, Arg15His,
and Arg15Leu) in humans are shown below the exons and introns. This
Arg15 residue, which is located in exon 2, is conserved in mouse. The
locations of the primers in exon 1 and 3 to investigate the effects of the
intron variant located in intron 2 (IVS2þ2T>C) are shown by arrows
(F [forward] and R [reverse] primers).
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Fig. 2. Ap2s1 missense variants affect conserved residues. Multiple protein sequence alignment of residues (A) 15 to 25 and (B) 118 to 128 of AP2s
orthologs show positions of Tyr20 (Y20) and Ile123 (I123), respectively. The Y20 and I123 residues are evolutionarily conserved, thereby indicating
that they may have important structure-function roles in AP2s. Conserved residues are shown in gray and the variants, both Asn (N), are shown in
red. Homology model of the AP2s protein (light brown) shows the predicted structural effects of (C) Tyr20Asn and (D) Ile123Asn. Wild-type residues
are shown in blue; mutant residues in orange. To date, FHH3 mutations involving only residue Arg15 (red) that lies within the second b-strand of
AP2s have been identiﬁed. This Arg15 residue is predicted to bind to a putative dileucine motif of the CaSR (black). The Tyr20 residue lies distal to
the Arg15 residue within b2 and on the opposite side of the dileucine binding region. The function of this AP2s region containing Tyr20, which is
not predicted to form polar contacts with other residues, is unknown. Importantly, the Asn variant does not disrupt or form new contacts, making it
difﬁcult to predict its effects. The Ile123 residue lies within a loop between the two terminal helices (a3–a4) of AP2s, which lies close to the AP2a
subunit. However, the Asn123 variant is not predicted to disrupt contacts with other AP2s or AP2a residues, thereby making it difﬁcult to predict its
effects.
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3.27–3.52mM) for wild-type–expressing cells, 3.69mM (95% CI
3.58–3.78mM) for Asn20–expressing cells, and 3.57mM (95%
CI 3.45–3.66mM) for Asn123–expressing cells (Fig. 3E). These
results reveal that although the Asn20 and Asn123 variants are
rare and involve evolutionarily conserved residues, they
nevertheless do not affect the structure of AP2s or CaSR-
mediated signaling. The mutant mice harboring the Asn20 and
Asn123 variants were therefore not rederived for in vivo studies.
Fig. 3. Intracellular calcium responses of the ENU-induced AP2s variants Tyr20Asn and Ile123Asn. (A) Fluorescence microscopy of HEK293 cells stably
expressing CaSR (HEK-CaSR) and transiently transfected with wild-type (WT), ENU variants (v) Tyr20Asn (Asn20) or Ile123Asn (Asn123), or the
FHH3-associated Arg15His (His15) mutant (m) pBI-CMV4-AP2S1 constructs. RFP expression in these cells indicates successful transfection and expression
by these constructs. Scale bar¼ 10mm. (B) Western blot analysis of lysates from HEK-CaSR cells used for ﬂow cytometry experiments. Transient
transfection with WT, variant Asn20 and Asn123, or mutant His15 constructs resulted in similar levels of overexpression of AP2s. Calnexin, a
housekeeping protein, was used as a loading control. Ca2þi response to changes in [Ca
2þ
e] of HEK-CaSR cells transfected with WT, (C) variant (v) Asn20,
(D) variant Asn123 or mutant (m) His15 expression constructs. The Ca2þi responses to changes in [Ca
2þ
e] are expressed as a percentage of the maximum
normalized responses and shown as themean SEM of 4 independent transfections. The FHH3-associated His15 AP2smutant led to a rightward shift in
the concentration-response curve, as previously reported,(8) whereas the Asn20 and Asn123 variants were indistinguishable fromWT. (E) Table showing
the mean half-maximal concentration (EC50) with 95% conﬁdence intervals (CI) and p values.
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Studies of 3 intronic Ap2s1 variants on splicing and AP2s
structure
Three intronic Ap2s1 variants were identiﬁed and these
comprised: a T-to-C transition at position 22 (IVS2-22T>C)
in intron 1 (Fig. 1); a T-to-C transition at position þ2
(IVS2þ2T>C) in intron 2, which disrupted the consensus donor
splice site gtgac to gcgac (Figs. 1 and 4); and a C-to-T transition
at position 17 (IVS5-17C>T) in intron 4 (Fig. 1). The effects of
these intronic variants were assessed using the Alternative
Splicing Site Predictor, and this revealed that IVS2-22T>C and
IVS5-17C>T would not result in splicing defects. However,
IVS2þ2T>C, which altered the invariant gt dinucleotide of
donor splice sites to gc and predicted a loss of a donor splice
site at the 5’ end of intron 2 of Ap2s1, could result in exon
skipping, activation of a cryptic splice site within exon 2, or
intron retention. These abnormalities could lead to a truncated
AP2s protein and yield a mouse with a deleted Ap2s1 allele
(knockout mouse model). The mouse harboring this
IVS2þ2T>C variant was therefore rederived to determine the
effect on splicing and on calcium metabolism. Heterozygous
mice (MGI designation: C3H.B6J-Ap2s1<m1H>/H) with the
donor splice site variant were viable, and the effects of the
IVS2þ2 donor splice site variant on splicing of the Ap2s1
gene were studied using RT-PCR with primers located in exons
1–3 (Fig. 1, Supplemental Table S1) and utilizing total RNA
obtained from a wild-type mouse and a mouse that was
heterozygous for the intron 2 variant. This revealed that the
intron 2 variant resulted in two PCR products of 267 bp and
216 bp compared with the one product of 267 bp from thewild-
type sample (Fig. 4A). DNA sequence analysis of these RT-PCR
products revealed that the variant altering the donor splice site
led to a loss of 51 nucleotides from exon 2 (Fig. 4B, C), with a
resulting in-frame deletion of 17 evolutionarily conserved
amino acids involving codons 35–51 (Fig. 4D). Thus, the ENU-
inducedmutation (T>C at IVS2þ2), which resulted in disruption
of the gt invariant dinucleotide of donor splice sites to gc,
resulted in utilization of an alternate cryptic donor splice site
(GTGCAC) within exon 2 that caused an in-frame deletion of
17 (del17) amino acids that form part of the a1 helix, a1-b3
loop, and the whole of the b3 strand of AP2s (Fig. 4E). The
effects of this mutation, which is designated del17, on Ap2s1
transcription and translation were studied using 4 kidneys
obtained from heterozygousmutantmice (Ap2s1þ/del17) (Fig. 5).
qRT-PCR analysis revealed no differences in the mRNA
expression levels of Ap2s1 between wild-type (Ap2s1þ/þ) and
mutant (Ap2s1þ/del17) mice, and between males and females
(Fig. 5A), which also did not have signiﬁcant differences in the
mRNA expression levels of the other genes encoding the AP2
subunits (a, b, and m) (Fig. 5A). Western blot analysis revealed
that the Ap2s1þ/del17 mice expressed only one protein product,
which corresponded to the full-length 17kDa AP2s protein
(Fig. 5B). However, expression of AP2s was reduced in the
mutant Ap2s1þ/del17 mice (fold-change of 0.30 0.01 for
Ap2s1þ/del17 mice compared with 1 0.24 for Ap2s1þ/þ mice,
p< 0.05), consistent with AP2s haplosufﬁciency and suggest-
ing that the mutant AP2s protein may be degraded or retained
within the protein synthesis pathway (Fig. 5C). However, this
difference in AP2s expression levels had no effect on the
expression of the AP2a, AP2b, or AP2m subunits (Fig. 5B, C).
The phenotypic effects of this AP2s haplosufﬁciency, due to the
ENU-induced donor splice site mutation of intron 2, on calcium
metabolism were further investigated in the mutant mice.
Phenotype studies of mutant mice with Ap2s1 donor
splice site mutation of intron 2
Analysis of offspring from crosses of heterozygous mutant
(Ap2s1+/del17) mice with C3H/HeH Ap2s1þ/þ mice revealed
the proportion of Ap2s1þ/del17 mice was as expected for a
Mendelian pattern of inheritance (51.97% Ap2s1+/+ versus
48.03% Ap2s1+/del17 [for 304 pups]). Ap2s1+/del17 mice were
fertile, grew at similar rates as their Ap2s1+/+ littermates, had
similar body weights, and appeared morphologically normal. To
determine the effects of the AP2s haplosufﬁciency, resulting
from the intron 2 donor splice site mutation of intron 2, on
calcium and electrolyte homeostasis in vivo, plasma and urine
samples from Ap2s1þ/del17 and Ap2s1þ/þ adult mice, aged 10 to
12weeks, were analyzed. This revealed no signiﬁcant differences
between Ap2s1þ/del17 and Ap2s1+/+ mice in plasma concen-
trations of albumin-adjusted calcium, phosphate, PTH, 1,25-
dihyroxyvitamin D, magnesium, creatinine, urea, sodium,
potassium, or alkaline phosphatase activity (Fig. 6, Table 1).
Furthermore, there were no signiﬁcant differences between
Ap2s1+/+ and Ap2s1+/del17 mice in the urinary excretion of
calcium, phosphate, sodium, or potassium (Table 2). These
studies indicate Ap2s1Iþ/del17 mice are not a model for FHH3 and
that mechanisms other than haplosufﬁciency of AP2s are
responsible for causing FHH3.
Initial matings of heterozygous (Ap2s1+/del17) intercrosses did
not yield any homozygote mutant (Ap2s1del17/del17) mice. For
example, assessment of 25 live offspring from heterozygous
intercrosses revealed that 9 were wild-type (Ap2s1þ/þ) mice, 16
were heterozygous (Ap2s1þ/del17) mice, and 0were homozygous
(Ap2s1del17/del17) mice, which deviated signiﬁcantly from that for
a Mendelian inheritance (chi-square test, p¼ 0.017, Table 3). We
therefore performed timed matings and analyzed the genotype
distribution at embryonic days 12.5 (E12.5), E9.5, and E3.5
(Table 3) to deﬁne the window of lethality. Analysis of 50
embryos at 12.5 days (E12.5), which is mid-gestation, revealed a
signiﬁcant deviation from the expected ratio for a Mendelian
inheritance (expected for wild-type (Ap2s1+/+): heterozygous
mutant (Ap2s1+/del17): homozygous mutants (Ap2s1del17/del17)
¼ 12:26:12 versus observed¼ 15:34:1, p< 0.0001) (Table 3).
Furthermore, the resorption rate at E12.5 was 19% in
pregnancies from the Ap2s1
+/del17
intercrosses, which is signiﬁ-
cantly (chi-square test, p¼ 0.012) higher than the reported
10.22% rate of spontaneous resorption in wild-type mice,(37)
indicating that most Ap2s1del17/del17 mice are dying before this
stage. Analysis of 60 embryos at an earlier stage, E9.5, revealed a
signiﬁcant deviation from the expected ratio, with no Ap2s1del17/
del17 embryos (Table 3) and with a signiﬁcantly high rate of
resorption of 40% (chi-square test, p< 0.001). However, the
expected Mendelian inheritance ratio was observed among 42
blastocysts (at E3.5) (Table 3), indicating that AP2smay play a
critical role inmouse embryonic development between E3.5 and
E9.5. Thus, this observed embryonic lethality of homozygous
mutant (Ap2s1del17/del17) mice indicates that AP2s has an
important role in embryonic development.
Discussion
Our studies have established a mouse with an Ap2s1 donor
splice site mutation of intron 2 (Fig. 1) that results in a loss of 17
amino acids (del17), which form parts of the a1 helix, a1-b3
loop, and the whole of theb3 strand of the AP2s subunit (Fig. 4).
This mutation leads to haplosufﬁciency in heterozygous mutant
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Fig. 4. Intron 2donor splice site variant (T>C) leads to abnormalmRNA splicingdue to loss of donor splice site andutilization of a cryptic donor splice site in
exon 2. (A) The effect of the intron 2 donor splice site variant T>C, which resulted in alteration of the invariant gt dinucleotide to gc, was assessed by RT-PCR
using primers located in Ap2s1 exons 1 and 3 (Fig. 1), utilizing total RNA obtained from a wild-type (WT) mouse and a mouse with the variant (v). Only one
RT-PCR product was obtained from the WT mouse at 267 bp, whereas two products were obtained from the heterozygous variant mouse, at 267 bp and
216 bp. S¼ sizemarker. (B) DNA sequence analysis of the variant heterozygousmouse revealed that the wild-type product had full-length exon 2, whereas
the variant product lacked the last 51 bpof exon 2 that resulted in a loss of 17 amino acids (codons 35–51). Thismutation, resulting in loss of 17 amino acids,
was therefore designated del17 and the heterozygousmouse referred to as Ap2s1+/del17. (C) Analysis of the DNA sequence of the variants in exon 2 revealed
that an in-framecryptic donor splice site locatedat codon35 that is notnormallyutilizedhasbeenused. (D)Multiple protein sequence alignment of residues
within exon2 and3ofAp2s1 revealed thatuseof the cryptic donor splice site resulted in an in-frame loss of 17evolutionarily conserved aminoacids, thereby
indicating that they likely have important structure-function roles in AP2s. (E) Three-dimensional modeling revealed that the 17 amino acids that are lost
because of the donor splice site mutation would lead to a loss of part of the a1 helix, the a1-b3 loop, and b3 strand (shown in green).
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mice (Ap2s1++/del17) (Fig. 5), which appear phenotypically normal
and are viable, in contrast to homozygous mutant mice
(Ap2s1del17/del17), which have embryonic lethality after the
blastocyst stage (E3.5) (Table 3). Our ﬁndings in mice with
mutant AP2s, which is involved in recognition of cargo proteins
with dileucine motifs for endocytosis, are similar to those
reported in mice with deletion of AP2m, which is the other small
subunit of AP2 and is involved in recognition of cargo proteins
with tyrosine-based motifs for endocytosis.(38) Thus, heterozy-
gous mutant AP2m mice (Ap2m+/) have an apparently normal
phenotype and are viable, whereas homozygous mutant mice
(Ap2m+/) were embryonically lethal and die before E3.5,
indicating an essential role for AP2m in early embryonic
development and in survival of embryonic cells.(39) Our results,
which demonstrate embryonic lethality of Ap2s1del17/del17 mice
between E3.5 and E9.5, indicate that AP2s also has critical roles
in early embryonic development stages, which include pattern-
ing of the embryo and organogenesis. Thus, AP2s may have
roles in patterning of the embryo, with development of the
anterior-posterior axis and dorsal-ventral axis, which occur at
E6.5, and left-right asymmetry and heart tube development,
which occur at E8.5;(40) and organogenesis of the thyroid
(commencing from E8.5), liver (commencing from E9.5), gut
(commencing before E9.5), lungs (commencing from E9.5),
pancreas (commencing from E9.5), and neural tube closure
commencing at E8.25.(41) However, a major distinction
between AP2s and AP2m null mice is that the former survive
beyond E3.5, whereas the latter do not. This indicates that
AP2s and AP2m have functionally distinct roles in develop-
ment that may be due to recognition of different develop-
mental endocytic cargos.(42) At present, the exact cargos of
AP2s and AP2m during embryonic development are unknown,
and further investigation of this could highlight the differ-
ences in stages of embryonic lethality. The early embryonic
lethality of these AP2s and AP2m null mice differs markedly to
the situation of mice null for AP2b, which is one of the larger
subunits of AP2. Thus, AP2b null mice survive to birth but have
a high perinatal mortality because of developmental defects,
including cleft palates.(43) The survival of AP2b null mice has
been attributed to the partial functional redundancy of the
b-subunit by its paralog in the AP1 complex, which is involved
in trans-Golgi-network trafﬁcking.(43) The b-subunits of AP1
and AP2 are 84% identical at the amino acid level,(43) thereby
allowing some interchangeability between the subunits.
However, other adaptor protein subunits are less similar,
including the m and s subunits, which cannot substitute for
Fig. 5. Effects of Ap2s1 intron 2 donor splice site on transcription and translation of AP2 subunits. Assessment of transcription and translation of genes
Ap2s1, Ap2a1, Ap2a2,Ap2b1, and Ap2m1 encoding the subunits AP2s, AP2a1, AP2a2, AP2b, and AP2m, respectively, of the AP2 heterotetrameric complex
in wild-type (Ap2s1+/+) mice and heterozygous mutant mice with the Ap2s1 intron 2 donor splice site mutation that results in loss of 17 amino acids
(Ap2s1þ/del17). (A) Quantitative RT-PCR (qRT-PCR) analysis of the Ap2s1, Ap2a1, Ap2a2, Ap2b1, and Ap2m1 transcripts using total RNA from kidneys of
Ap2s1+/+ and Ap2s1þ/del17 male and female mice. All data were normalized to the geometric mean of three housekeeper genes (Ccnd1, Gapdh, Pgk1) and
expressed as a fold-change compared with wild-type (Ap2s1+/+) mice. Mean values for the respective groups are indicated by horizontal solid lines. Each
point represents an individual mouse (males¼ squares; females¼ circles). There were no signiﬁcant differences in the Ap2s1, Ap2a1, Ap2a2, Ap2b1, and
Ap2m1 transcript levels between Ap2s1þ/þ and Ap2s1þ/del17 mice or between sexes. (B) Assessment of AP2 subunits (a, b, m, s) by Western blot analysis,
using kidney lysates from Ap2s1þ/þ and Ap2s1þ/del17 mice. Calnexin was used as the housekeeping protein and loading control. Each lane represents 1
mouse, and 2male and 2 femalemice were used for each of the Ap2s1þ/þ and Ap2s1þ/del17 mice. (C) Densitometry analysis of the expression levels of AP2
subunits (a, b, m, s). Data are from a total of 4 mice (2 males and 2 females) in each group. Data frommales and females were combined as the transcript
levels were similar in both sexes. Mean values for the respective groups are indicated by horizontal solid lines. Each point represents an individual mouse
(males¼ squares; females¼ circles). AP2s was signiﬁcantly (p< 0.05) reduced by 50% in Ap2s1+/del17 mice, consistent with AP2s haplosufﬁciency,
whereas other subunits were unaffected.
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each other,(44) and this may help to explain the observed early
embryonic lethality in mice null for AP2m and AP2s.
In contrast to the early embryonic lethality of homozygous
mutant Ap2s1 mice (Ap2s1del17/del17), heterozygous mutant
Ap2s1 mice (Ap2s1+/del17) were viable and appeared normal,
and this is similar to the ﬁndings in heterozygous Ap2m+/ and
Ap2b+/ mice.(39,43) However, the Ap2s1+/del17 did not have the
plasma and urine biochemical abnormalities associated with
FHH3, and these included an absence of hypercalcemia and
hypocalciuria (Fig. 6, Tables 1 and 2). These ﬁndings indicate that
AP2s haplosufﬁciency (Fig. 5), which is observed in these
heterozygous mutant mice, is not responsible for FHH3. This is
consistent with our studies in FHH3 patients that reported that
FHH3-associated AP2s mutations, which are all missense
mutations of the Arg15 residue that binds to the dileucine
motifs of cargo proteins, exert a dominant-negative effect on
the function of the AP2 complex.(12) In this context, our ﬁndings
related to the two missense AP2s variants Tyr20Asn and
Ile123Asn (Fig. 1) help to illustrate some important points. These
two missense AP2s variants (Figs. 1 and 2), which involved
evolutionarily conserved residues and were predicted to be
damaging and disease-causing, had not been previously
reported in the ExAc or NHLBI-ESP databases, that contain
data from >66,000 individuals,(36) thereby further supporting
the likelihood that they may be disease-causing mutations.
However, these missense ENU-induced variants, Tyr20Asn and
Ile123Asn, were found not to alter CaSR-mediated signaling by
in vitro assays (Fig. 3), and the molecular mechanism for this
tolerance of the altered residues at codons 20 and 123 is likely
owing to the position of the respective residues within the AP2s
protein. Thus, Tyr20 lies within a region distal to the region of the
AP2s that interacts with dileucine motifs and is not close to
Fig. 6. Plasma calcium, phosphate, and PTH studies in Ap2s1+/del17 mice. (A, B) Plasma-adjusted calcium, (C, D) plasma phosphate, and (E, F) plasma PTH
concentrations in male and female wild-type (Ap2s1þ/þ) and heterozygous mutant (Ap2s1+/del17) mice. Each point represents an individual mouse. Mean
values for the respective groups are indicated by horizontal solid lines. Ap2s1+/+ and Ap2s1+/del17 mice had similar plasma calcium, phosphate, and PTH
concentrations, and these were also similar between the two sexes.
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regions of the protein known to be involved in interactions with
other AP2 complex proteins (Fig. 2). Similarly, Ile123 lies within a
loop structure close to the binding regions with other AP2
complex proteins, but the mutation is not predicted to disrupt
any structures within AP2s or to generate steric hindrance
within the structure (Fig. 2). Moreover, it seems that there may
be a low frequency of Ap2s1 mutations as only ﬁve missense
mutations and no splice or nonsense mutations have been
reported in the ExAc and NHLBI-ESP databases.(36) Indeed, the
observed frequencies of missense and nonsense AP2S1 variants
is signiﬁcantly lower than that expected from the ExAc
database(36) (observed Ap2s1 variants versus ExAc gene variants:
Table 1. Plasma Biochemical Studies of Ap2s1+/del17 Mice
Male Female
Ap2s1+/+ Ap2s1þ/del17 Ap2s1+/+ Ap2s1þ/del17
n¼ 12 n¼ 10 n¼ 10 n¼ 12
Sodium (mmol/L) 150.75 0.30 151.20 0.20 148.60 0.54 148.83 0.37
Potassium (mmol/L) 5.46 0.30 5.25 0.11 4.73 0.07 4.71 0.06
Urea (mmol/L) 12.24 0.42 13.07 0.39 8.58 0.48 8.51 0.21
Creatinine (mmol/L) 15.64 0.48 16.22 0.69 14.09 0.66 14.42 0.39
Calcium (mmol/L)a 2.36 0.02 2.34 0.02 2.42 0.01 2.41 0.02
Magnesium (mmol/L) 0.79 0.03 0.74 0.02 0.79 0.02 0.81 0.02
Phosphate (mmol/L) 1.92 0.76 1.90 0.05 2.09 0.08 2.04 0.07
ALP (U/L) 101.33 3.75 100.20 3.94 146.10 4.73 147.00 6.57
PTH (ng/L) 302.98 42.53 338.47 57.28 296.26 58.24 303.25 24.13
1,25D (pmol/L) 68.77 3.82 59.97 4.25 88.67 6.45 85.87 6.78
Plasma biochemical analysis was performed on 10- to 12-week-old Ap2s1þ/del17 and Ap2s1þ/þ mice. All values are expressed as mean SEM.
ALP¼ alkaline phosphatase activity; PTH¼parathyroid hormone; 1,25D¼ 1,25-dihydroxyvitamin D.
aPlasma calcium concentrations were adjusted for the plasma albumin concentration.
Table 2. Urine Biochemical Studies of Ap2s1+/del17 Mice
Male Female
Ap2s1+/+ Ap2s1þ/del17 Ap2s1+/+ Ap2s1þ/del17
n¼ 12 n¼ 10 n¼ 10 n¼ 12
24-hour calcium 2.09 0.15 2.44 0.26 3.29 0.32 4.42 0.25
Calcium/creatinine 0.34 0.026 0.36 0.034 0.44 0.032 0.51 0.04
Fractional excretion calcium 0.002 0.0001 0.003 0.0003 0.003 0.0002 0.003 0.0002
Fractional excretion phosphate 0.04 0.006 0.04 0.010 0.02 0.009 0.02 0.006
Fractional excretion sodium 0.01 0.0003 0.01 0.0004 0.01 0.0003 0.01 0.0003
Fractional excretion potassium 0.29 0.01 0.29 0.01 0.27 0.01 0.28 0.01
Urine biochemical analysis was performed on 10- to 12-week-old Ap2s1þ/del17 and Ap2s1þ/þ mice, in metabolic cages, using urine samples collected
over a 24-hour period. Urinary calcium excretion values are shown as mmol/24 hours. All values are expressed as mean SEM.
Table 3. Progeny From Ap2s1+/del17Ap2s1+/del17 Intercrosses
Genotype
Ap2s1+/+ Ap2s1þ/del17 Ap2s1del17/del17 Total p Value
Stage
Live birth Expecteda 6 13 6 25 0.017
Observed 9 16 0
E12.5 Expecteda 12 26 12 50 0.0001
Observed 15 34 1
E9.5 Expecteda 15 30 15 60 0.0001
Observed 27 33 0
Blastocysta (E3.5) Expecteda 10 22 10 42 0.31
Observed 10 26 6
E¼ embryonic day.
Statistical analyses were performed by chi-square analysis comparing expected to observed numbers for each litter.
aExpected ratio from heterozygous intercrosses for Mendelian inheritance of wild-type (Ap2s1þ/þ): heterozygotes (Ap2s1þ/del17): homozygotes
(Ap2s1del17/del17)¼ 1:2:1.
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missense¼ 0.008% versus 0.1%; nonsense¼ 0% versus 0.01%,
chi-square p< 0.0001). This suggests that mutations that are
predicted to disrupt the structure of AP2s, or its functions such
as cargo recognition, are not tolerated. Thus, our studies
highlight the limitations of bioinformatics and protein predic-
tion software, which may be inaccurate,(45) and the importance
of acquiring data from multiple sources, including modeling of
mutations to predict possible outcomes of missense changes
and in vitro functional characterization to assess known roles of
the protein.
In summary, we have identiﬁed ﬁve ENU-induced Ap2s1
variants and demonstrated that one of these resulted in loss of a
donor splice site in intron 2 and was associated with a loss of 17
amino acids (del17) that form part of the a1 helix, a1-b3 loop,
and b3 strand of the AP2s subunit. In vivo investigations of
heterozygous Ap2s1+/del17 mice revealed them to have AP2s
haplosufﬁciency that was associated with a normal appearance,
normal plasma, and urine calcium concentrations and
normal plasma PTH concentrations. However, homozygous
Ap2s1del17/del17 mice had embryonic lethality commencing after
E3.5, indicating an important role for AP2s in embryonic
patterning and organogenesis.
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